detail content area
Cancers, 2019. 11(8), 1108-1154, DOI: https://doi.org/10.3390/cancers11081154
Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer
Yea Eun Kang, Jung Tae Kim;Mi Ae Lim;Chan Oh; Lihua Liu;Seung-Nam Jung;Ho-Ryun Won;Kyungmin Lee;JaeWon Chang;Hyon-Seung Yi;Hyun Jin Kim;Bon Jeong Ku;Minho Shong;Bon Seok Koo
Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, andenergy metabolism; however, its e ects in tumors remain poorly understood. To understand therole of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 weremeasured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levelsof FGF21, FGF receptors (FGFRs), and -klotho (KLB) were investigated in human thyroid tissues.The cell viability, migrating cells, and invading cells were measured in PTC cells after treatment withrecombinant FGF21. Higher serum levels of FGF21 were found in patients with thyroid cancer thanin control participants, and were significantly associated with body mass index (BMI), fasting glucoselevels, triglyceride levels, tumor stage, lymphovascular invasion, and recurrence. Serum FGF21levels were positively correlated with the BMI in patients with PTC, and significantly associated withrecurrence. Recombinant FGF21 led to tumor aggressiveness via activation of the FGFR signalingaxis and epithelial-to-mesenchymal transition (EMT) signaling in PTC cells, and AZD4547, an FGFRtyrosine kinase inhibitor, attenuated the e ects of FGF21. Hence, FGF21 may be a new biomarker forpredicting tumor progression, and targeting FGFR may be a novel therapy for the treatment of obesepatients with PTC.
- DOI: https://doi.org/10.3390/cancers11081154
- ISBN or ISSN: 1097-0142
- 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
- This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.